Lilly Asia Ventures And Fidelity Boost Innovent Biologics Investment To Deepen Exposure To China’s Biologics Market
This article was originally published in PharmAsia News
Executive Summary
Lilly Asia Ventures looks to biologics growth in making latest investment in China’s Innovent with partner Fidelity Biosciences.